Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya, Japan.
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Sugitani, Toyama, Japan.
JAMA Surg. 2021 May 1;156(5):418-428. doi: 10.1001/jamasurg.2021.0108.
In distal pancreatectomy (DP), the splenic vein is isolated from the pancreatic parenchyma prior to being ligated and divided to prevent intra-abdominal hemorrhage from the splenic vein stump with pancreatic fistula (PF). Conversely, dissecting the splenic vein with the pancreatic parenchyma is easy and time-saving.
To establish the safety of combined division of the splenic vein compared with separate division of the splenic vein.
DESIGN, SETTING, AND PARTICIPANTS: This study was designed as a multicenter prospective randomized phase 3 trial. All results were analyzed using the modified intent-to-treat set. Patients undergoing DP for pancreatic body and tail tumors were eligible for inclusion. Patients were randomly assigned between August 10, 2016, and July 30, 2019.
Patients were centrally randomized (1:1) to either separate division of the splenic vein or combined division of the splenic vein.
The primary end point was the incidence of grade B/C PF, and the incidence of intra-abdominal hemorrhage was included as one of the secondary end points.
A total of 318 patients were randomly assigned, and 2 patients were excluded as ineligible. Of the 316 remaining patients, 150 (50.3%) were male. The modified intent-to-treat population constituted 159 patients (50.3%) in the separate division group and 157 patients (49.7%) in the combined division group. In the modified intent-to-treat set, the proportion of grade B/C PF in the separate division group was 27.1% (42 of 155) vs 28.6% (44 of 154) in the combined division group (adjusted odds ratio, 1.108; 95% CI, 0.847-1.225; P = .047), demonstrating noninferiority of the combined division of the splenic vein against separate division. The incidence of postoperative intra-abdominal hemorrhage in the 2 groups was identical at 1.3%.
This study demonstrated noninferiority of the combined division of the splenic vein compared with separate division of the splenic vein regarding safety. Thus, isolating the splenic vein from the pancreatic parenchyma is deemed unnecessary.
ClinicalTrials.gov Identifier: NCT02871804.
在远端胰腺切除术(DP)中,脾静脉在结扎和分离之前与胰腺实质分离,以防止胰腺瘘(PF)引起的脾静脉残端腹腔内出血。相反,与胰腺实质一起解剖脾静脉既简单又省时。
确定联合分离脾静脉与单独分离脾静脉的安全性。
设计、地点和参与者:本研究设计为多中心前瞻性随机 3 期试验。所有结果均采用修改后的意向治疗集进行分析。符合胰腺体尾部肿瘤行 DP 治疗的患者纳入本研究。患者于 2016 年 8 月 10 日至 2019 年 7 月 30 日期间被随机分组。
患者被中央随机分配(1:1)至单独分离脾静脉或联合分离脾静脉。
主要终点为 B/C 级 PF 的发生率,将腹腔内出血的发生率作为次要终点之一。
共随机分配 318 例患者,2 例患者因不符合条件被排除。在其余 316 例患者中,150 例(50.3%)为男性。修改后的意向治疗人群包括单独分离组 159 例(50.3%)和联合分离组 157 例(49.7%)。在修改后的意向治疗集内,单独分离组的 B/C 级 PF 比例为 27.1%(42/155),联合分离组为 28.6%(44/154)(调整后的优势比,1.108;95%CI,0.847-1.225;P=0.047),表明联合分离脾静脉与单独分离脾静脉相比不劣效。两组术后腹腔内出血发生率相同,均为 1.3%。
本研究表明,联合分离脾静脉与单独分离脾静脉在安全性方面无差异。因此,没有必要将脾静脉与胰腺实质分离。
ClinicalTrials.gov 标识符:NCT02871804。